Scholarlink

Introduction <p>Seborrheic dermatitis (SD) is a common, chronic inflammatory skin condition affecting sebaceous gland-rich areas of the skin. The multifactorial etiology of SD involves sebocyte activity, skin microbiome dysbiosis, and immune factors. Various treatment options exist for management of SD.</p> Methods <p>A PubMed search conducted on November 1, 2024 using the terms “seborrheic dermatitis” and “treatment” (restricted to 2019–2024) yielded 389 results, from which relevant papers and additional references were included in this review.</p> Discussion <p>Topical antifungals, topical corticosteroids, and topical calcineurin inhibitors are first-line treatments for SD; however, long-term use of each of these may be limited by varying side effects. Roflumilast foam is a newly approved topical with potential to become a first-line treatment. Myriad systemic treatments exist as second- and third-line treatments for cases of moderate-to-severe and/or recalcitrant SD. Procedural interventions of varying efficacy exist.</p> Conclusions <p>The treatment of SD requires an individualized approach, utilizing a range of topical, systemic, and procedural interventions. The advent of new treatments like roflumilast foam offers novel, well-tolerated, and safer options than what has been available in the past.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Child and Adult Seborrheic Dermatitis: A Narrative Review of the Current Treatment Landscape

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月14日

查看全文
  • Savanna I. Vidal,
  • Nikita Menta,
  • Lawrence Green

摘要

Introduction

Seborrheic dermatitis (SD) is a common, chronic inflammatory skin condition affecting sebaceous gland-rich areas of the skin. The multifactorial etiology of SD involves sebocyte activity, skin microbiome dysbiosis, and immune factors. Various treatment options exist for management of SD.

Methods

A PubMed search conducted on November 1, 2024 using the terms “seborrheic dermatitis” and “treatment” (restricted to 2019–2024) yielded 389 results, from which relevant papers and additional references were included in this review.

Discussion

Topical antifungals, topical corticosteroids, and topical calcineurin inhibitors are first-line treatments for SD; however, long-term use of each of these may be limited by varying side effects. Roflumilast foam is a newly approved topical with potential to become a first-line treatment. Myriad systemic treatments exist as second- and third-line treatments for cases of moderate-to-severe and/or recalcitrant SD. Procedural interventions of varying efficacy exist.

Conclusions

The treatment of SD requires an individualized approach, utilizing a range of topical, systemic, and procedural interventions. The advent of new treatments like roflumilast foam offers novel, well-tolerated, and safer options than what has been available in the past.